Oral nitrofurantoin monohydrate/macrocrystals — Competitive Intelligence Brief

Oral nitrofurantoin monohydrate/macrocrystals (Oral nitrofurantoin monohydrate/macrocrystals) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrofuran antibiotic. Area: Infectious Disease.

phase 3 Nitrofuran antibiotic Bacterial DNA and RNA synthesis; bacterial nitroreductase Infectious Disease Small molecule

Target snapshot

Oral nitrofurantoin monohydrate/macrocrystals (Oral nitrofurantoin monohydrate/macrocrystals) — NICHD Global Network for Women's and Children's Health. Nitrofurantoin inhibits bacterial DNA and RNA synthesis by interfering with bacterial enzyme systems, making it bactericidal against susceptible urinary tract pathogens.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral nitrofurantoin monohydrate/macrocrystals TARGET	Oral nitrofurantoin monohydrate/macrocrystals	NICHD Global Network for Women's and Children's Health	phase 3	Nitrofuran antibiotic	Bacterial DNA and RNA synthesis; bacterial nitroreductase
nitrofurantoin monohydrate/macrocrystalline capsules	nitrofurantoin monohydrate/macrocrystalline capsules	University of California, San Diego	marketed	Nitrofuran antibiotic	Bacterial DNA and ribosomal proteins (non-specific after activation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitrofuran antibiotic class)

1. NICHD Global Network for Women's and Children's Health · 1 drug in this class
2. University of California, San Diego · 1 drug in this class